2m 2m 2m 2m 2m 2m 2m
- $38.7BMarket Cap
- -14.74%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Haleon Sp ADR (HLN)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 16
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
The global dietary supplements market is projected to grow from USD 151.82 billion in 2026 to USD 187.22 billion by 2031 at a CAGR of 4.28%. Growth is driven by preventive healthcare adoption, aging populations, and shifting consumer preferences toward convenient formats like gummies and liquids. Asia-Pacific leads market share, while clean-label and personalized nutrition solutions are reshaping the industry.
01/23/2026, 3:45 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Key Executives
- Brian James McNamara
- Dawn Amanda Allen
- Tamara Rogers
- Namrata Patel
- Line De Decker
Current Ownership Distribution
- Institutions5.3B (73.09%)
- Mutual Funds1.9B (26.91%)
- Insiders0 (0.00%)
- Other0 (0.00%)